265 related articles for article (PubMed ID: 28198380)
21. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
[TBL] [Abstract][Full Text] [Related]
22. Targeting a cell state common to triple-negative breast cancers.
Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
24. A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
Koh M; Lee JC; Min C; Moon A
Bioorg Med Chem; 2013 Apr; 21(8):2305-2313. PubMed ID: 23490148
[TBL] [Abstract][Full Text] [Related]
25. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
26. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
[TBL] [Abstract][Full Text] [Related]
27. Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer.
Kung PP; Martinez R; Zhu Z; Zager M; Blasina A; Rymer I; Hallin J; Xu M; Carroll C; Chionis J; Wells P; Kozminski K; Fan J; Guicherit O; Huang B; Cui M; Liu C; Huang Z; Sistla A; Yang J; Murray BW
Mol Cancer Ther; 2014 Aug; 13(8):2104-15. PubMed ID: 24928852
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
29. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
30. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
31. Advances in the 1-phenanthryl-tetrahydroisoquinoline series of PAK4 inhibitors: potent agents restrain tumor cell growth and invasion.
Hao C; Li X; Song S; Guo B; Guo J; Zhang J; Zhang Q; Huang W; Wang J; Lin B; Cheng M; Li F; Zhao D
Org Biomol Chem; 2016 Aug; 14(32):7676-90. PubMed ID: 27454186
[TBL] [Abstract][Full Text] [Related]
32. Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo.
Xiang L; Xu X; Zhang S; Cai D; Dai X
Free Radic Biol Med; 2018 Aug; 124():205-213. PubMed ID: 29870749
[TBL] [Abstract][Full Text] [Related]
33. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
34. Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis.
Bhattarai PY; Oh CH; Kim G; Kim MS; Lee BS; Choi HS
Anticancer Res; 2020 Sep; 40(9):5081-5090. PubMed ID: 32878796
[TBL] [Abstract][Full Text] [Related]
35. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
36. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
[TBL] [Abstract][Full Text] [Related]
37. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
[TBL] [Abstract][Full Text] [Related]
38. Lactate dehydrogenase downregulation mediates the inhibitory effect of diallyl trisulfide on proliferation, metastasis, and invasion in triple-negative breast cancer.
Cheng SY; Yang YC; Ting KL; Wen SY; Viswanadha VP; Huang CY; Kuo WW
Environ Toxicol; 2017 Apr; 32(4):1390-1398. PubMed ID: 27566995
[TBL] [Abstract][Full Text] [Related]
39. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
40. Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.
Fan L; Tian M; Liu Y; Deng Y; Liao Z; Xu J
Oncotarget; 2017 May; 8(18):29823-29832. PubMed ID: 28415735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
